E. Juhász

发表

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

G. Giaccone, F. Cappuzzo, T. Ciuleanu, 2010, The Lancet. Oncology.

Calcifying liver metastases in a case of primary lung cancer.

E. Juhász, Z. Balikó, B. Anga, 1997, Chest.

Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer

J. Milanowski, J. von Pawel, P. Baas, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumour biomarker and plasma time course data from ABIGAIL, a phase II study of 1st-line bevacizumab + chemotherapy in advanced non-squamous non-small-cell lung cancer (ns-NSCLC)

T. Mok, E. Juhász, S. Scherer, 2012 .

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

L. Sequist, J. Nemunaitis, E. Juhász, 2014, Journal of Immunotherapy for Cancer.

Subclinical pulmonary involvement assessed by bronchoalveolar lavage in patients with early undifferentiated connective tissue disease.

E. Juhász, L. Czirják, A. Komócsi, 2001, Clinical and experimental rheumatology.

Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First‐Line Therapy in Patients with Extensive‐Disease Small Cell Lung Cancer

R. Govindan, S. Novello, E. Juhász, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer

L. Urban, S. Ramalingam, V. Giranda, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.

T. Mok, E. Juhász, M. Reck, 2014, Lung cancer.

Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC.

L. Urban, S. Ramalingam, V. Giranda, 2015 .

The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study

E. Juhász, G. Losonczy, E. Tolnay, 2018, Oncology letters.

Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.

S. Walzer, E. Juhász, G. Klingelschmitt, 2013, European journal of cancer.

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

H. Groen, M. Socinski, C. Gridelli, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC.

G. Giaccone, F. Cappuzzo, T. Ciuleanu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

G. Giaccone, D. Dunlop, J. Nemunaitis, 2015, European journal of cancer.

Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)

R. Govindan, S. Novello, E. Juhász, 2016 .

Cisplatin–vinorelbine chemotherapy in non-small cell lung cancer is safe and well tolerated: results of a retrospective Hungarian clinical data analysis

E. Juhász, L. Tamási, M. Budai, 2009, Expert opinion on drug safety.

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)

T. Mok, E. Juhász, P. Delmar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

L. Urban, S. Ramalingam, V. Giranda, 2016, Clinical Cancer Research.

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

J. Soria, L. Amler, E. Juhász, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

E. Juhász, I. Bodrogi, J. Horti, 2008, Cancer Chemotherapy and Pharmacology.

A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC).

J. Soria, E. Juhász, P. Zatloukal, 2010 .

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

C. Azzoli, K. Kelly, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA40_PRTARGET: A RANDOMIZED, PHASE II TRIAL COMPARING VINTAFOLIDE VERSUS VINTAFOLIDE PLUS DOCETAXEL, VERSUS DOCETAXEL ALONE IN SECOND-LINE TREATMENT OF FOLATE-RECEPTOR-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

N. Hanna, R. Ramlau, E. Juhász, 2014 .

Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study

H. Groen, L. Tye, T. Ciuleanu, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

RANDOMIZED PHASE II STUDY OF SUNITINIB (SU) PLUS ERLOTINIB (E) VS. PLACEBO (P) PLUS E FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

H. Groen, M. Socinski, C. Gridelli, 2010 .

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer

P. Hegde, J. von Pawel, E. Juhász, 2018, The oncologist.